1. Signaling Pathways
  2. PI3K/Akt/mTOR
  3. mTOR

mTOR (哺乳动物雷帕霉素靶蛋白)

Mammalian target of Rapamycin

mTOR(哺乳动物雷帕霉素靶蛋白)是一种由人类 mTOR 基因编码的蛋白质。mTOR 是一种丝氨酸/苏氨酸蛋白激酶,可调节细胞生长、细胞增殖、细胞运动、细胞存活、蛋白质合成和转录。mTOR 属于磷脂酰肌醇 3-激酶相关激酶蛋白家族。mTOR 整合上游通路的输入,包括生长因子和氨基酸。mTOR 还能感知细胞营养、氧气和能量水平。mTOR 通路在人类疾病中失调,例如糖尿病、肥胖症、抑郁症和某些癌症。雷帕霉素通过与其细胞内受体 FKBP12 结合来抑制 mTOR。FKBP12-雷帕霉素复合物直接与 mTOR 的 FKBP12-雷帕霉素结合 (FRB) 域结合,从而抑制其活性。

mTOR (mammalian target of Rapamycin) is a protein that in humans is encoded by the mTOR gene. mTOR is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, and transcription. mTOR belongs to the phosphatidylinositol 3-kinase-related kinase protein family. mTOR integrates the input from upstream pathways, including growth factors and amino acids. mTOR also senses cellular nutrient, oxygen, and energy levels. The mTOR pathway is dysregulated in human diseases, such as diabetes, obesity, depression, and certain cancers. Rapamycin inhibits mTOR by associating with its intracellular receptor FKBP12. The FKBP12-rapamycin complex binds directly to the FKBP12-Rapamycin Binding (FRB) domain of mTOR, inhibiting its activity.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-178362
    CAII/VII-IN-1 Inhibitor
    CAII/VII-IN-1 是一种口服活性的 hCA II (KI = 12.3 nM) 和 hCA VII (KI = 22.6 nM) 抑制剂,对 hCA I 没有表现出明显的活性。CAII/VII-IN-1 在体内 Pilocarpine (HY-B0726A) 诱发的癫痫模型中表现出优异的神经保护活性。CAII/VII-IN-1 可以上调 KCC2 并抑制 mTOR,发挥神经保护作用。CAII/VII-IN-1 没有表现出任何明显的神经毒性作用或肝肾功能的改变。CAII/VII-IN-1 可用于癫痫的研究。
    CAII/VII-IN-1
  • HY-112774
    ICSN3250 Inhibitor
    ICSN3250 是一种 halitulin 类似物,也是一种特异性的 mTORC1 抑制剂。ICSN3250 直接结合 mTOR 的 FRB 结构域并置换磷脂酸 (PA),逆转 mTORC1 的激活。ICSN3250 通过不依赖 caspase 的细胞死亡机制,在癌细胞中显示出纳摩尔浓度级别的高细胞毒性。ICSN3250 能特异性抑制 mTORC1 通路,在癌细胞中诱导自噬 (autophagy) 并引起 G0-G1 期细胞周期阻滞。ICSN3250 可用于癌症研究。
    ICSN3250
  • HY-N0281R
    Daphnetin (Standard)

    瑞香素 (标准品)

    Inhibitor
    Daphnetin (Standard) 是 Daphnetin 的分析标准品。本产品用于研究及分析应用。Daphnetin (7,8-dihydroxycoumarin) 是一种香豆素衍生物,可来源于 Genus Daphne,是一种口服有效的蛋白激酶抑制剂 (protein kinase),对 EGFR、PKA 和 PKCIC50 值分别为 7.67 μM、9.33 μM 和 25.01 μM。Daphnetin 触发活性氧诱导的细胞凋亡 (apoptosis) 和通过调节 AMPK/Akt/mTOR 途径诱导细胞保护性自噬(autophagy)。Daphnetin 具有抗炎活性,并抑制 TNF-α、IL-1 、ROS 和 MDA 的产生。Daphnetin 具有杀疟活性。瑞香素可用于类风湿关节炎、癌症和抗疟疾研究。
    Daphnetin (Standard)
  • HY-170912
    Topo I/II-IN-2 Inhibitor
    Topo I/II-IN-2 (Compound 3g) 是一种 Topo ITopo II 抑制剂。Topo I/II-IN-2 对NCI-H446 细胞和 NCI-H104 8细胞的抑制活性的 IC50 值为 1.30 μM和 1.42 μM。Topo I/II-IN-2 诱导线粒体凋亡 (Apoptosis),线粒体功能紊乱,诱导活性生成。Topo I/II-IN-2 抑制 PI3K/Akt/mTOR 通路,在体外阻止 SCLC (小细胞肺癌) 细胞的增殖、侵袭和迁移。
    Topo I/II-IN-2
  • HY-16769
    Panulisib Inhibitor
    Panulisib (P7170; AK151761) 是一种口服有效的 PI3K (IC50 = 2.2 nM) 和 mTOR (IC50 = 4.4 nM) 抑制剂。Panulisib 抑制 ALK1DNA-PK,这两种酶分别参与血管生成和 DNA 修复,IC50 分别为 47 nM 和 1.5 nM。Panulisib 抑制细胞增殖和凋亡 (apoptosis)。Panulisib 可用于研究乳腺癌和非小细胞肺癌。
    Panulisib
  • HY-122352
    OSU-03013 Inhibitor
    OSU-03013 是 Celecoxib (HY-14398) 的类似物。OSU-03013 可促进细胞凋亡 (apoptosis),上调 E-cadherin,并下调 β-cateninc-mycWnt1N-cadherin。OSU-03013 可降低细胞迁移和侵袭能力。OSU-03013 通过调节 WntmTOR 的表达来抑制结肠癌 (CC) 细胞的增殖。OSU-03013 可用于结肠癌的研究。
    OSU-03013
  • HY-181020
    Deltafluorine Inhibitor
    Deltafluorine 是一种磷酸二酯酶 δ (PDEδ) 抑制剂,其 IC50 为 27 nM,KD 为 148 nM。Deltafluorine 可共价修饰 PDEδ 配体结合位点中的特异性谷氨酸残基 p.E88,干扰其分子伴侣功能。Deltafluorine 可抑制 MAPKAkt-mTOR 通路的信号传导,降低 ERK1/2 的表达水平。Deltafluorine 可在 Kras 驱动的肺腺癌自发性小鼠模型中减小肿瘤体积。Deltafluorine 可用于肺腺癌的相关研究。
    Deltafluorine
  • HY-N2217R
    Rotundic acid (Standard)

    铁冬青酸 (标准品)

    Inhibitor
    Rotundic acid (Standard) 是 Rotundic acid 的分析标准品。本产品用于研究及分析应用。Rotundic acid 是一种从铁冬青 (Ilex rotunda Thunb) 中获得的三萜类化合物,可通过 AKT/mTORMAPK 途径在肝细胞癌中诱导 DNA 损伤和细胞凋亡。Rotundic acid 具有抗炎和保护心脏的能力。
    Rotundic acid (Standard)
  • HY-179464
    CC-M-1 Inhibitor
    CC-M-1 是一种高效且选择性的 PI3K/mTOR 抑制剂。CC-M-1 对 PI3Kα/β/γ/δmTORIC50 值分别为 0.68、1.02、1.03、8.03 和 15 nM。CC-M-1 可抑制结直肠癌细胞系的增殖,包括 HCT-116 (IC50 = 0.38 μM) 和 HT-29 (IC50 = 1.70 μM)。CC-M-1 可用于结直肠癌 (CRC) 的研究。
    CC-M-1
  • HY-176948
    M-1111 Inhibitor
    M-1111 是一种 Rapa-Link 抑制剂。M-1111 由 Rapamycin (HY-10219) 和活性位点 mTOR 抑制剂共价连接而成。M-1111 对 mTORC1 信号通路 (pS6p4E-BP1) 具有强抑制活性。M-1111 对多种癌细胞具有纳摩尔级别的抑制活性。M-1111 完全抑制 p4E-BP1,不抑制 pAkt S473。M-1111 可用于研究肝癌、肾癌、结直肠癌。
    M-1111
  • HY-10116
    PI-540 Inhibitor
    PI-540 是双环噻吩并嘧啶衍生物,是口服有效的 PI3K 抑制剂。PI-540 具有抗癌细胞增殖和高组织分布度的特性。PI-540 可抑制 PI3K 不同亚型,IC50s 分别为 10 nM (P110α),3510 nM (P110β),410 nM (P110δ),33110 nM (P110γ)。PI-540 还抑制 mTOR (IC50: 61 nM) 和 DNA-PK (IC50: 525 nM)。
    PI-540
  • HY-181650
    T133 Inhibitor
    T133 是一种具有口服活性的 ATP 竞争性 mTOR 抑制剂,其 IC50 为 0.34 nM,Ki 为 0.17 nM。T133 可抑制 AKTS6K14EBP1 的磷酸化。T133 能够抑制癌细胞的增殖与迁移,诱导细胞凋亡 (apoptosis)、细胞周期阻滞及自噬 (autophagy)。T133 在异种移植小鼠模型中呈现出剂量依赖性的抗肿瘤功效。T133 可用于癌症研究,例如胃癌和肺癌。
    T133
  • HY-N0047R
    Polyphyllin I (Standard)

    重楼皂苷I (标准品)

    Inhibitor
    Polyphyllin I (Standard)是 Polyphyllin I 的分析标准品。本产品用于研究及分析应用。Polyphyllin I 是一种从 Paris polyphylla 中提取的生物活性成分,具有很强的抗肿瘤活性。Polyphyllin I 是 JNK 信号通路的激活剂,也是 PDK1/Akt/mTOR 信号传导的抑制剂。Polyphyllin I 诱导自噬,G2/M 期阻滞和细胞凋亡。
    Polyphyllin I (Standard)
  • HY-108959
    D-87503 Inhibitor
    D-87503 是 PI3k/Akt/mTOR 的有效抑制剂,对 PI3kErk2IC50 分别为 62 nM 和 0.76 μM。D-87503 可有效抑制 PI3k/Akt/mTOR 信号通路的下游靶底物 AktRsk1 激酶。
    D-87503
  • HY-203618
    PI3K/mTOR ligand-1 Ligand
    PI3K/mTOR ligand-1 是一种用于 PROTAC 靶蛋白 (PI3K/mTOR) 的配体。PI3K/mTOR ligand-1 可用于合成GP262。
    PI3K/mTOR ligand-1
  • HY-15268
    PP487 Inhibitor
    PP487 是一种酪氨酸激酶/PI(3)Ks 双重抑制剂,其对 DNA-PKmTORHckSrcEGFREphB4PDGFRIC50 值分别为 0.017 μM、0.072 μM、0.004 μM、0.01 μM、0.55 μM、0.22 μM 和 < 0.01 μM。PP487 可以用于癌症的研究。
    PP487
  • HY-161857
    Akt/mTOR-IN-1 Inhibitor
    Akt/mTOR-IN-1 (Compound 8r) 是 AKT/mTOR 信号通路抑制剂,IC50 值为 0.8 µM,具有抗癌活性。Akt/mTOR-IN-1 可以降低 Caspase 3 的表达,并提高自噬蛋白 Cyclin B1 的表达,诱导细胞自噬和凋亡。Akt/mTOR-IN-1 可用于非小细胞肺癌 (NSCLC) 领域研究。
    Akt/mTOR-IN-1
  • HY-15901A
    LGB321 monohydrochloride Inhibitor
    LGB321 monohydrochloride 是一种有效的、选择性且具有口服活性的 ATP 竞争性小分子抑制剂,可抑制所有三种 PIM 激酶。LGB321 monohydrochloride 在血液恶性肿瘤来源的多种细胞系中抑制增殖、mTOR-C1 信号通路和 BAD 磷酸化。LGB321 monohydrochloride 可用于血液恶性肿瘤的研究。
    LGB321 monohydrochloride
  • HY-W142432S
    Perfluoroundecanoic acid-13C7

    全氟十一烷酸-13C7

    Perfluoroundecanoic acid-13C713C 标记的 Perfluoroundecanoic acid (HY-W142432)。Perfluoroundecanoic acid 是一种全氟烷基物质 (PFAS)。Perfluoroundecanoic acid 是一种口服有效的氧化应激诱导剂。Perfluoroundecanoic acid 促进巨噬细胞 M2 极化,激活 Wnt/β-catenin 信号通路,并增强 β-catenin 的核积累。Perfluoroundecanoic acid 诱导的 M2 表型巨噬细胞在体外和体内加速肿瘤进展。Perfluoroundecanoic acid 通过氧化应激诱导雄性 Swiss 小鼠的 DNA 损伤、生殖和病理生理功能障碍。Perfluoroundecanoic acid 通过诱导氧化应激和自噬 (Autophagy) 抑制青春期雄性大鼠的 Leydig 细胞发育。Perfluoroundecanoic acid 加速 1 型糖尿病小鼠模型中胰岛炎的发展。 Perfluoroundecanoic acid 可用于卵巢癌、1 型糖尿病和炎症研究。
    Perfluoroundecanoic acid-<sup>13</sup>C<sub>7</sub>
  • HY-178431
    MT-44 Inhibitor
    MT-44 是一种高选择性和强效的 mTOR 抑制剂,其 IC50 值为 49.4 nM。MT-44 能够抑制癌细胞的增殖、迁移和侵袭。MT-44 可以诱导细胞凋亡 (apoptosis) 和活性氧 (ROS) 的产生,并导致 G2/M 期阻滞。MT-44 能够激活 cGAS/STING 通路。MT-44 可用于癌症研究,如三阴性乳腺癌的研究。
    MT-44
目录号 产品名 / 同用名 应用 反应物种

The mammalian target of rapamycin (mTOR) signaling pathway integrates both intracellular and extracellular signals and serves as a central regulator of cell metabolism, growth, proliferation and survival[1]. mTOR is the catalytic subunit of two distinct complexes called mTORC1 and mTORC2. mTORC1 comprises DEPTOR, PRAS40, RAPTOR, mLST8, mTOR, whereas mTORC2 comprises DEPTOR, mLST8, PROTOR, RICTOR, mSIN1, mTOR[2]. Rapamycin binds to FKBP12 and inhibits mTORC1 by disrupting the interaction between mTOR and RAPTOR. mTORC1 negatively regulates autophagy through multiple inputs, including inhibitory phosphorylation of ULK1 and TFEB. mTORC1 promotes protein synthesis through activation of the translation initiation promoter S6K and through inhibition of the inhibitory mRNA cap binding 4E-BP1, and regulates glycolysis through HIF-1α. It promotes de novo lipid synthesis through the SREBP transcription factors. mTORC2 inhibits FOXO1,3 through SGK and Akt, which can lead to increased longevity. The complex also regulates actin cytoskeleton assembly through PKC and Rho kinase[3]

 

Growth factors: Growth factors can signal to mTORC1 through both PI3K-Akt and Ras-Raf-MEK-ERK axis. For example, ERK and RSK phosphorylate TSC2, and inhibit it.

 

Insulin Receptor: The activated insulin receptor recruits intracellular adaptor protein IRS1. Phosphorylation of these proteins on tyrosine residues by the insulin receptor initiates the recruitment and activation of PI3K. PIP3 acts as a second messenger which promotes the phosphorylation of Akt and triggers the Akt-dependent multisite phosphorylation of TSC2. TSC is a heterotrimeric complex comprised of TSC1, TSC2, and TBC1D7, and functions as a GTPase activating protein (GAP) for the small GTPase Rheb, which directly binds and activates mTORC1. mTORC2 primarily functions as an effector of insulin/PI3K signaling. 

 

Wnt: The Wnt pathway activates mTORC1. Glycogen synthase kinase 3β (GSK-3β) acts as a negative regulator of mTORC1 by phosphorylating TSC2. mTORC2 is activated by Wnt in a manner dependent on the small GTPase RAC1[4].

 

Amino acids: mTORC1 senses both lysosomal and cytosolic amino acids through distinct mechanisms. Amino acids induce the movement of mTORC1 to lysosomal membranes, where the Rag proteins reside. A complex named Ragulator, interact with the Rag GTPases, recruits them to lysosomes through a mechanism dependent on the lysosomal v-ATPase, and is essential for mTORC1 activation. In turn, lysosomal recruitment enables mTORC1 to interact with GTP-bound RHEB, the end point of growth factor. Cytosolic leucine and arginine signal to mTORC1 through a distinct pathway comprised of the GATOR1 and GATOR2 complexes.    

 

Stresses: mTORC1 responds to intracellular and environmental stresses that are incompatible with growth such as low ATP levels, hypoxia, or DNA damage. A reduction in cellular energy charge, for example during glucose deprivation, activates the stress responsive metabolic regulator AMPK, which inhibits mTORC1 both indirectly, through phosphorylation and activation of TSC2, as well as directly through the phosphorylation of RAPTOR. Sestrin1/2 are two transcriptional targets of p53 that are implicated in the DNA damage response, and they potently activate AMPK, thus mediating the p53-dependent suppression of mTOR activity upon DNA damage. During hypoxia, mitochondrial respiration is impaired, leading to low ATP levels and activation of AMPK. Hypoxia also affects mTORC1 in AMPK-independent ways by inducing the expression of REDD1, the protein products of which then suppress mTORC1 by promoting the assembly of TSC1-TSC2[2].

 

Reference:

[1]. Laplante M, et al.mTOR signaling at a glance.J Cell Sci. 2009 Oct 15;122(Pt 20):3589-94. 
[2]. Zoncu R, et al. mTOR: from growth signal integration to cancer, diabetes and ageing.Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35. 
[3]. Johnson SC, et al. mTOR is a key modulator of ageing and age-related disease.Nature. 2013 Jan 17;493(7432):338-45.
[4]. Shimobayashi M, et al. Making new contacts: the mTOR network in metabolism and signalling crosstalk.Nat Rev Mol Cell Biol. 2014 Mar;15(3):155-62.

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.